Last reviewed · How we verify

Dapagliflozin or Empagliflozin

Yonsei University · FDA-approved active Small molecule Quality 5/100

Dapagliflozin or Empagliflozin is a Small molecule drug developed by Yonsei University. It is currently FDA-approved.

At a glance

Generic nameDapagliflozin or Empagliflozin
SponsorYonsei University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dapagliflozin or Empagliflozin

What is Dapagliflozin or Empagliflozin?

Dapagliflozin or Empagliflozin is a Small molecule drug developed by Yonsei University.

Who makes Dapagliflozin or Empagliflozin?

Dapagliflozin or Empagliflozin is developed and marketed by Yonsei University (see full Yonsei University pipeline at /company/yonsei-university).

What development phase is Dapagliflozin or Empagliflozin in?

Dapagliflozin or Empagliflozin is FDA-approved (marketed).

Related